HRP20251339T1 - Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba - Google Patents
Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotrebaInfo
- Publication number
- HRP20251339T1 HRP20251339T1 HRP20251339TT HRP20251339T HRP20251339T1 HR P20251339 T1 HRP20251339 T1 HR P20251339T1 HR P20251339T T HRP20251339T T HR P20251339TT HR P20251339 T HRP20251339 T HR P20251339T HR P20251339 T1 HRP20251339 T1 HR P20251339T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pyrrolo
- amino
- propylsulfonating
- reagent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694698P | 2018-07-06 | 2018-07-06 | |
| US201862776642P | 2018-12-07 | 2018-12-07 | |
| US201962855071P | 2019-05-31 | 2019-05-31 | |
| PCT/IB2019/055683 WO2020008391A1 (en) | 2018-07-06 | 2019-07-03 | Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof |
| EP19766356.0A EP3817810B1 (en) | 2018-07-06 | 2019-07-03 | Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20251339T1 true HRP20251339T1 (hr) | 2025-12-19 |
Family
ID=67928862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20251339TT HRP20251339T1 (hr) | 2018-07-06 | 2019-07-03 | Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10815240B2 (https=) |
| EP (1) | EP3817810B1 (https=) |
| JP (1) | JP7437646B2 (https=) |
| KR (1) | KR102568464B1 (https=) |
| CN (1) | CN112384282B (https=) |
| AU (1) | AU2019299666B2 (https=) |
| BR (1) | BR112020025701A2 (https=) |
| CA (1) | CA3105161C (https=) |
| ES (1) | ES3045115T3 (https=) |
| HR (1) | HRP20251339T1 (https=) |
| IL (1) | IL279926B2 (https=) |
| MX (2) | MX2020013896A (https=) |
| TW (1) | TWI709562B (https=) |
| WO (1) | WO2020008391A1 (https=) |
| ZA (1) | ZA202100196B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3969458A4 (en) | 2019-05-13 | 2023-05-17 | Borah, Inc. | CHEMICAL COMPOUNDS |
| CN113637018A (zh) | 2020-04-27 | 2021-11-12 | 苏州晶云药物科技股份有限公司 | 磺酰胺类化合物的晶型及其制备方法 |
| CN112279785B (zh) * | 2020-10-29 | 2022-08-16 | 苏利制药科技江阴有限公司 | 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法 |
| CN113583992B (zh) * | 2021-07-15 | 2023-06-27 | 华东理工大学 | 一种还原胺化酶及其在仲胺合成中的应用 |
| JP2024533433A (ja) * | 2021-09-10 | 2024-09-12 | ハイヘ バイオファーマ カンパニー，リミティド | Ｅｎｐｐ１阻害活性を有するヒドロキサム酸系化合物及びその使用 |
| ES2993658B2 (es) | 2023-06-27 | 2025-07-02 | Moehs Iberica Sl | (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib |
| ES3040374A1 (es) * | 2024-04-30 | 2025-10-30 | Moehs Iberica Sl | Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP4126781B2 (ja) | 1998-10-26 | 2008-07-30 | 宇部興産株式会社 | １−スルホニルピラゾール誘導体及びその製造方法 |
| JP2003005323A (ja) | 2001-06-20 | 2003-01-08 | Konica Corp | 熱現像写真感光材料及び画像形成方法 |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| WO2011017800A1 (en) | 2009-08-10 | 2011-02-17 | Bellus Health (International) Limited | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid |
| WO2013007582A2 (en) | 2011-07-08 | 2013-01-17 | Syngenta Participations Ag | Processes for the preparation of thietanamine |
| CU24275B1 (es) * | 2013-02-22 | 2017-10-05 | Pfizer | Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos |
| EP3180344B1 (en) * | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
-
2019
- 2019-07-03 KR KR1020217003518A patent/KR102568464B1/ko active Active
- 2019-07-03 CN CN201980045496.5A patent/CN112384282B/zh active Active
- 2019-07-03 ES ES19766356T patent/ES3045115T3/es active Active
- 2019-07-03 TW TW108123441A patent/TWI709562B/zh active
- 2019-07-03 AU AU2019299666A patent/AU2019299666B2/en active Active
- 2019-07-03 MX MX2020013896A patent/MX2020013896A/es unknown
- 2019-07-03 IL IL279926A patent/IL279926B2/en unknown
- 2019-07-03 HR HRP20251339TT patent/HRP20251339T1/hr unknown
- 2019-07-03 BR BR112020025701-0A patent/BR112020025701A2/pt unknown
- 2019-07-03 CA CA3105161A patent/CA3105161C/en active Active
- 2019-07-03 EP EP19766356.0A patent/EP3817810B1/en active Active
- 2019-07-03 US US16/502,703 patent/US10815240B2/en active Active
- 2019-07-03 WO PCT/IB2019/055683 patent/WO2020008391A1/en not_active Ceased
- 2019-07-04 JP JP2019124976A patent/JP7437646B2/ja active Active
-
2020
- 2020-09-29 US US17/036,849 patent/US11254684B2/en active Active
- 2020-12-16 MX MX2023006842A patent/MX2023006842A/es unknown
-
2021
- 2021-01-12 ZA ZA2021/00196A patent/ZA202100196B/en unknown
-
2022
- 2022-01-10 US US17/572,089 patent/US12018031B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023006842A (es) | 2023-06-22 |
| EP3817810C0 (en) | 2025-09-17 |
| EP3817810B1 (en) | 2025-09-17 |
| US12018031B2 (en) | 2024-06-25 |
| KR20210029234A (ko) | 2021-03-15 |
| CA3105161A1 (en) | 2020-01-09 |
| MX2020013896A (es) | 2021-03-09 |
| KR102568464B1 (ko) | 2023-08-21 |
| WO2020008391A1 (en) | 2020-01-09 |
| TW202017929A (zh) | 2020-05-16 |
| US10815240B2 (en) | 2020-10-27 |
| US11254684B2 (en) | 2022-02-22 |
| IL279926A (en) | 2021-03-01 |
| CN112384282B (zh) | 2024-07-02 |
| IL279926B1 (en) | 2023-08-01 |
| AU2019299666A1 (en) | 2021-01-07 |
| US20200123159A1 (en) | 2020-04-23 |
| ES3045115T3 (en) | 2025-11-27 |
| CN112384282A (zh) | 2021-02-19 |
| IL279926B2 (en) | 2023-12-01 |
| JP2020007308A (ja) | 2020-01-16 |
| CA3105161C (en) | 2022-11-15 |
| BR112020025701A2 (pt) | 2021-03-16 |
| US20210009601A1 (en) | 2021-01-14 |
| AU2019299666B2 (en) | 2024-07-11 |
| JP7437646B2 (ja) | 2024-02-26 |
| TWI709562B (zh) | 2020-11-11 |
| US20220127274A1 (en) | 2022-04-28 |
| EP3817810A1 (en) | 2021-05-12 |
| ZA202100196B (en) | 2022-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251339T1 (hr) | Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba | |
| ES2728247T3 (es) | Método para la preparación cíclica de taurina a partir de una sal de metal alcalino de ácido hidroxietil sulfónico y una sal de metal alcalino de ácido vinil sulfónico | |
| IL278766B1 (en) | Molecule, n-(3-chloro-1 (pyridin-3-yl)-h 1-pyrazol-4-yl)-2-(methylsulfonyl)propanamide for use in pest control | |
| CL2021000611A1 (es) | Proceso para preparar n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida por acoplamiento entre un indazol y una pirimidina; ciclación para formar un azabenzimidazol y desprotección del grupo indazol con tfa puro (divisional de la solicitud no. 201803423) | |
| EA201991055A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛ[1,5-a]ПИРИМИДИНОВ И ИХ СОЛЕЙ | |
| UA80298C2 (en) | 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands | |
| RU2016151208A (ru) | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы | |
| JP2015536296A5 (https=) | ||
| JP2017504576A5 (https=) | ||
| HUE027943T2 (en) | Process for the preparation of tetrazole-substituted anthranilic acid amide derivatives and a novel crystalline modification of these derivatives | |
| KR20150028992A (ko) | 2-(5-브로모-4-(4-사이클로프로필나프탈렌-1-일)-4ｈ-1,2,4-트리아졸-3-일티오)아세트산의 제조 | |
| JP2020007308A5 (https=) | ||
| RU2015143643A (ru) | Соль омекамтива мекарбила и способ ее получения | |
| JP2013049690A5 (https=) | ||
| HRP20211903T1 (hr) | Stabilni kristalni oblik tipiracil hidroklorida i postupak kristalizacije istog | |
| CN107001289A (zh) | N‑酰基‑(3‑取代的)‑(8‑取代的)‑5,6‑二氢‑[1,2,4]三唑并[4,3‑a]吡嗪的新手性合成 | |
| HRP20130950T1 (hr) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina | |
| CO6241155A2 (es) | [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo | |
| AU2019206560B2 (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
| HRP20110465T1 (hr) | Modulatori aktivnosti receptora kemokina, kristalni oblici i postupak | |
| CN106748873A (zh) | 一种维生素b5机械研磨固相制备方法 | |
| HRP20210062T1 (hr) | Kristal spoja s aktivnošću inhibiranja jak | |
| HRP20210820T1 (hr) | Inovativna priprema i kristalizacija iosimenola | |
| ES2523346T3 (es) | Un proceso para preparar sal de tricloroaminoplatinato y los productos obtenidos en el mismo | |
| JP2008543805A5 (https=) |